Serum  ||| S:0 E:6 ||| JJ
selenium  ||| S:6 E:15 ||| JJ
status  ||| S:15 E:22 ||| NN
in  ||| S:22 E:25 ||| IN
Graves ||| S:25 E:31 ||| NNP
'  ||| S:31 E:33 ||| POS
disease  ||| S:33 E:41 ||| NN
with  ||| S:41 E:46 ||| IN
and  ||| S:46 E:50 ||| CC
without  ||| S:50 E:58 ||| IN
orbitopathy ||| S:58 E:69 ||| NNS
:  ||| S:69 E:71 ||| :
a  ||| S:71 E:73 ||| DT
case-control  ||| S:73 E:86 ||| JJ
study  ||| S:86 E:92 ||| NN
Selenium  ||| S:92 E:101 ||| NNP
is  ||| S:101 E:104 ||| VBZ
effective  ||| S:104 E:114 ||| JJ
in  ||| S:114 E:117 ||| IN
improving  ||| S:117 E:127 ||| VBG
quality  ||| S:127 E:135 ||| NN
of  ||| S:135 E:138 ||| IN
life  ||| S:138 E:143 ||| NN
and  ||| S:143 E:147 ||| CC
reducing  ||| S:147 E:156 ||| VBG
the  ||| S:156 E:160 ||| DT
progression  ||| S:160 E:172 ||| NN
of  ||| S:172 E:175 ||| IN
active  ||| S:175 E:182 ||| JJ
Graves ||| S:182 E:188 ||| NNP
'  ||| S:188 E:190 ||| POS
orbitopathy ||| S:190 E:201 ||| NN
.  ||| S:201 E:203 ||| .
The  ||| S:203 E:207 ||| DT
effect  ||| S:207 E:214 ||| NN
of  ||| S:214 E:217 ||| IN
correcting  ||| S:217 E:228 ||| VBG
relative  ||| S:228 E:237 ||| JJ
selenium  ||| S:237 E:246 ||| JJ
deficiency  ||| S:246 E:257 ||| NN
on  ||| S:257 E:260 ||| IN
improving  ||| S:260 E:270 ||| VBG
Graves ||| S:270 E:276 ||| NNP
'  ||| S:276 E:278 ||| POS
orbitopathy  ||| S:278 E:290 ||| NN
is  ||| S:290 E:293 ||| VBZ
unknown ||| S:293 E:300 ||| JJ
,  ||| S:300 E:302 ||| ,
as  ||| S:302 E:305 ||| IN
baseline  ||| S:305 E:314 ||| JJ
selenium  ||| S:314 E:323 ||| JJ
levels  ||| S:323 E:330 ||| NNS
have  ||| S:330 E:335 ||| VBP
not  ||| S:335 E:339 ||| RB
previously  ||| S:339 E:350 ||| RB
been  ||| S:350 E:355 ||| VBN
measured ||| S:355 E:363 ||| VBN
.  ||| S:363 E:365 ||| .
The  ||| S:365 E:369 ||| DT
study  ||| S:369 E:375 ||| NN
aims  ||| S:375 E:380 ||| VBZ
to  ||| S:380 E:383 ||| TO
determine  ||| S:383 E:393 ||| VB
whether  ||| S:393 E:401 ||| IN
serum  ||| S:401 E:407 ||| JJ
selenium  ||| S:407 E:416 ||| JJ
levels  ||| S:416 E:423 ||| NNS
are  ||| S:423 E:427 ||| VBP
reduced  ||| S:427 E:435 ||| VBN
in  ||| S:435 E:438 ||| IN
patients  ||| S:438 E:447 ||| NNS
with  ||| S:447 E:452 ||| IN
Graves ||| S:452 E:458 ||| NNP
'  ||| S:458 E:460 ||| POS
disease  ||| S:460 E:468 ||| NN
with  ||| S:468 E:473 ||| IN
orbitopathy  ||| S:473 E:485 ||| NNS
( ||| S:485 E:486 ||| -LRB-
GO ||| S:486 E:488 ||| NNP
)  ||| S:488 E:490 ||| -RRB-
compared  ||| S:490 E:499 ||| VBN
with  ||| S:499 E:504 ||| IN
without  ||| S:504 E:512 ||| IN
orbitopathy  ||| S:512 E:524 ||| NNS
( ||| S:524 E:525 ||| -LRB-
GD ||| S:525 E:527 ||| NNP
) ||| S:527 E:528 ||| -RRB-
.  ||| S:528 E:530 ||| .
A  ||| S:530 E:532 ||| DT
prospective ||| S:532 E:543 ||| JJ
,  ||| S:543 E:545 ||| ,
case-control  ||| S:545 E:558 ||| JJ
study  ||| S:558 E:564 ||| NN
performed  ||| S:564 E:574 ||| VBN
between  ||| S:574 E:582 ||| IN
2009  ||| S:582 E:587 ||| CD
and  ||| S:587 E:591 ||| CC
2012  ||| S:591 E:596 ||| CD
at  ||| S:596 E:599 ||| IN
endocrine  ||| S:599 E:609 ||| NN
and  ||| S:609 E:613 ||| CC
ophthalmology  ||| S:613 E:627 ||| JJ
clinics  ||| S:627 E:635 ||| NNS
in  ||| S:635 E:638 ||| IN
Australia ||| S:638 E:647 ||| NNP
.  ||| S:647 E:649 ||| .
A  ||| S:649 E:651 ||| DT
total  ||| S:651 E:657 ||| NN
of  ||| S:657 E:660 ||| IN
198  ||| S:660 E:664 ||| CD
patients  ||| S:664 E:673 ||| NNS
with  ||| S:673 E:678 ||| IN
Graves ||| S:678 E:684 ||| NNP
'  ||| S:684 E:686 ||| POS
disease  ||| S:686 E:694 ||| NN
participated  ||| S:694 E:707 ||| VBD
in  ||| S:707 E:710 ||| IN
the  ||| S:710 E:714 ||| DT
study ||| S:714 E:719 ||| NN
:  ||| S:719 E:721 ||| :
101  ||| S:721 E:725 ||| CD
with  ||| S:725 E:730 ||| IN
Graves ||| S:730 E:736 ||| NNP
'  ||| S:736 E:738 ||| POS
orbitopathy  ||| S:738 E:750 ||| NN
and  ||| S:750 E:754 ||| CC
97  ||| S:754 E:757 ||| CD
without  ||| S:757 E:765 ||| IN
Graves ||| S:765 E:771 ||| NNP
'  ||| S:771 E:773 ||| POS
orbitopathy ||| S:773 E:784 ||| NN
.  ||| S:784 E:786 ||| .
Serum  ||| S:786 E:792 ||| JJ
selenium  ||| S:792 E:801 ||| JJ
levels  ||| S:801 E:808 ||| NNS
in  ||| S:808 E:811 ||| IN
both  ||| S:811 E:816 ||| DT
groups ||| S:816 E:822 ||| NNS
.  ||| S:822 E:824 ||| .
Mean  ||| S:824 E:829 ||| VB
serum  ||| S:829 E:835 ||| JJ
selenium  ||| S:835 E:844 ||| JJ
levels  ||| S:844 E:851 ||| NNS
were  ||| S:851 E:856 ||| VBD
significantly  ||| S:856 E:870 ||| RB
lower  ||| S:870 E:876 ||| JJR
in  ||| S:876 E:879 ||| IN
GO  ||| S:879 E:882 ||| NNP
( ||| S:882 E:883 ||| -LRB-
1·10  ||| S:883 E:888 ||| FW
±  ||| S:888 E:890 ||| FW
0·18  ||| S:890 E:895 ||| FW
μm ||| S:895 E:897 ||| FW
)  ||| S:897 E:899 ||| -RRB-
than  ||| S:899 E:904 ||| IN
in  ||| S:904 E:907 ||| IN
GD  ||| S:907 E:910 ||| NNP
( ||| S:910 E:911 ||| -LRB-
1·19  ||| S:911 E:916 ||| FW
±  ||| S:916 E:918 ||| FW
0·20  ||| S:918 E:923 ||| FW
μm ||| S:923 E:925 ||| FW
)  ||| S:925 E:927 ||| -RRB-
( ||| S:927 E:928 ||| -LRB-
P  ||| S:928 E:930 ||| NN
=  ||| S:930 E:932 ||| SYM
0·001 ||| S:932 E:937 ||| CD
) ||| S:937 E:938 ||| -RRB-
.  ||| S:938 E:940 ||| .
Mean  ||| S:940 E:945 ||| VB
selenium  ||| S:945 E:954 ||| JJ
levels  ||| S:954 E:961 ||| NNS
appeared  ||| S:961 E:970 ||| VBD
to  ||| S:970 E:973 ||| TO
decrease  ||| S:973 E:982 ||| VB
in  ||| S:982 E:985 ||| IN
parallel  ||| S:985 E:994 ||| NN
with  ||| S:994 E:999 ||| IN
increasing  ||| S:999 E:1010 ||| VBG
severity  ||| S:1010 E:1019 ||| NN
of  ||| S:1019 E:1022 ||| IN
GO ||| S:1022 E:1024 ||| NNP
;  ||| S:1024 E:1026 ||| :
selenium  ||| S:1026 E:1035 ||| JJ
level  ||| S:1035 E:1041 ||| NN
was  ||| S:1041 E:1045 ||| VBD
1·19  ||| S:1045 E:1050 ||| CD
±  ||| S:1050 E:1052 ||| CD
0·20  ||| S:1052 E:1057 ||| CD
μm  ||| S:1057 E:1060 ||| NN
in  ||| S:1060 E:1063 ||| IN
GD ||| S:1063 E:1065 ||| NNP
,  ||| S:1065 E:1067 ||| ,
1·10  ||| S:1067 E:1072 ||| CD
±  ||| S:1072 E:1074 ||| CD
0·19  ||| S:1074 E:1079 ||| CD
μm  ||| S:1079 E:1082 ||| NN
in  ||| S:1082 E:1085 ||| IN
moderate-to-severe  ||| S:1085 E:1104 ||| NNP
GO  ||| S:1104 E:1107 ||| NNP
and  ||| S:1107 E:1111 ||| CC
1·09  ||| S:1111 E:1116 ||| CD
±  ||| S:1116 E:1118 ||| CD
0·17  ||| S:1118 E:1123 ||| CD
μm  ||| S:1123 E:1126 ||| NN
in  ||| S:1126 E:1129 ||| IN
sight-threatening  ||| S:1129 E:1147 ||| NNP
GO  ||| S:1147 E:1150 ||| NNP
( ||| S:1150 E:1151 ||| -LRB-
P  ||| S:1151 E:1153 ||| NN
=  ||| S:1153 E:1155 ||| SYM
0·003 ||| S:1155 E:1160 ||| CD
) ||| S:1160 E:1161 ||| -RRB-
.  ||| S:1161 E:1163 ||| .
Serum  ||| S:1163 E:1169 ||| JJ
selenium  ||| S:1169 E:1178 ||| JJ
levels  ||| S:1178 E:1185 ||| NNS
remained  ||| S:1185 E:1194 ||| VBD
significantly  ||| S:1194 E:1208 ||| RB
lower  ||| S:1208 E:1214 ||| JJR
in  ||| S:1214 E:1217 ||| IN
GO  ||| S:1217 E:1220 ||| NNP
after  ||| S:1220 E:1226 ||| IN
adjusting  ||| S:1226 E:1236 ||| VBG
for  ||| S:1236 E:1240 ||| IN
age ||| S:1240 E:1243 ||| NN
,  ||| S:1243 E:1245 ||| ,
smoking  ||| S:1245 E:1253 ||| NN
status ||| S:1253 E:1259 ||| NN
,  ||| S:1259 E:1261 ||| ,
thyroidectomy ||| S:1261 E:1274 ||| NN
,  ||| S:1274 E:1276 ||| ,
radioactive  ||| S:1276 E:1288 ||| JJ
iodine  ||| S:1288 E:1295 ||| JJ
treatment  ||| S:1295 E:1305 ||| NN
and  ||| S:1305 E:1309 ||| CC
residential  ||| S:1309 E:1321 ||| JJ
location ||| S:1321 E:1329 ||| NN
.  ||| S:1329 E:1331 ||| .
Serum  ||| S:1331 E:1337 ||| JJ
selenium  ||| S:1337 E:1346 ||| JJ
levels  ||| S:1346 E:1353 ||| NNS
are  ||| S:1353 E:1357 ||| VBP
lower  ||| S:1357 E:1363 ||| JJR
in  ||| S:1363 E:1366 ||| IN
patients  ||| S:1366 E:1375 ||| NNS
with  ||| S:1375 E:1380 ||| IN
GO  ||| S:1380 E:1383 ||| NNP
compared  ||| S:1383 E:1392 ||| VBN
with  ||| S:1392 E:1397 ||| IN
GD  ||| S:1397 E:1400 ||| NNP
in  ||| S:1400 E:1403 ||| IN
an  ||| S:1403 E:1406 ||| DT
Australian  ||| S:1406 E:1417 ||| JJ
study  ||| S:1417 E:1423 ||| NN
population  ||| S:1423 E:1434 ||| NN
with  ||| S:1434 E:1439 ||| IN
marginal  ||| S:1439 E:1448 ||| JJ
selenium  ||| S:1448 E:1457 ||| JJ
status ||| S:1457 E:1463 ||| NN
.  ||| S:1463 E:1465 ||| .
Relative  ||| S:1465 E:1474 ||| JJ
selenium  ||| S:1474 E:1483 ||| JJ
deficiency  ||| S:1483 E:1494 ||| NN
may  ||| S:1494 E:1498 ||| MD
be  ||| S:1498 E:1501 ||| VB
an  ||| S:1501 E:1504 ||| DT
independent  ||| S:1504 E:1516 ||| JJ
risk  ||| S:1516 E:1521 ||| NN
factor  ||| S:1521 E:1528 ||| NN
for  ||| S:1528 E:1532 ||| IN
orbitopathy  ||| S:1532 E:1544 ||| NN
in  ||| S:1544 E:1547 ||| IN
patients  ||| S:1547 E:1556 ||| NNS
with  ||| S:1556 E:1561 ||| IN
Graves ||| S:1561 E:1567 ||| NNP
'  ||| S:1567 E:1569 ||| POS
disease ||| S:1569 E:1576 ||| NN
.  ||| S:1576 E:1578 ||| .
